Saturday, September 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 8, 2025

Beat the Market the Zacks Way: Veracyte, Las Vegas Sands, 3M in Focus

View original at finance.yahoo.com
Beat the Market the Zacks Way: Veracyte, Las Vegas Sands, 3M in Focus Last Friday, the three most widely followed benchmark indexes closed a winning week…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Zacks Focus List portfolio returned 18.3% in 2025 through September 30th vs. +14.8% for S&P 500

    80% confidence
  • Hypothetical portfolio of Zacks Rank #1 stocks returned +8.64% in 2025 through September 1st vs. +7.60% for the S&P 500

    80% confidence
  • Gains driven by renewed hopes that Fed will cut interest rates soon after recent economic data showed consumer spending firming and inflation remaining tame

    80% confidence
  • Top 10 portfolio returned +26.47% in 2025 through September vs. +14.84% for S&P 500

    80% confidence
  • Top 10 portfolio has produced cumulative return of +2,553.1% since 2012 through September 2025 vs. +545.2% for S&P 500

    80% confidence
  • ECDP returned -3.17% in Q2 2025 vs. S&P 500's +10.94% and NOBL's -0.09%

    80% confidence
  • Zacks Rank #1 portfolio returned +22.4% in 2024 vs. +28% for S&P 500

    80% confidence
  • ECAP portfolio seeks to minimize capital loss by holding companies with proven 20+ year track record of surviving recessions

    80% confidence
  • Zacks Model Portfolio has outperformed S&P 500 by more than 12 percentage points since 1988, generating 23.8% annualized return vs. 11.3% for S&P 500

    80% confidence
  • Focus List portfolio returned +18.41% in 2024 vs. +25.04% for S&P 500

    80% confidence
  • ECAP returned +0.20% in Q2 2025 vs. S&P 500's +10.94% gain

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com